View in EDS

Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.

Saved in:
Bibliographic Details
Title: Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.
Authors: Pandya H; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Patel M; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Gillen M; Creek Lane PK, LLC, Waterford, Virginia., Reddy J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, The Discovery Centre, Biomedical Campus, Cambridge, UK., Bednarczyk A; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland., Kokot M; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland., Tan Y; Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Mississauga, Ontario, Canada., Heijer M; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca, Mölndal, Gothenburg, Sweden., Andersson M; Respiratory and Immunology, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg, Sweden., Petullo D; Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Jassal M; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, Gaithersburg, Maryland. Electronic address: mandeep.jassal@astrazeneca.com.
Source: Clinical therapeutics [Clin Ther] 2026 Jan; Vol. 48 (1), pp. 73-80. Date of Electronic Publication: 2025 Dec 04.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41344973
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pandya+H%22">Pandya H</searchLink>; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Patel+M%22">Patel M</searchLink>; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Gillen+M%22">Gillen M</searchLink>; Creek Lane PK, LLC, Waterford, Virginia.<br /><searchLink fieldCode="AU" term="%22Reddy+J%22">Reddy J</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, The Discovery Centre, Biomedical Campus, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Bednarczyk+A%22">Bednarczyk A</searchLink>; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Kokot+M%22">Kokot M</searchLink>; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Tan+Y%22">Tan Y</searchLink>; Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Mississauga, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Heijer+M%22">Heijer M</searchLink>; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca, Mölndal, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Andersson+M%22">Andersson M</searchLink>; Respiratory and Immunology, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Petullo+D%22">Petullo D</searchLink>; Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Jassal+M%22">Jassal M</searchLink>; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, Gaithersburg, Maryland. Electronic address: mandeep.jassal@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227706726%22">Clinical therapeutics</searchLink> [Clin Ther] 2026 Jan; Vol. 48 (1), pp. 73-80. <i>Date of Electronic Publication: </i>2025 Dec 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Excerpta+Medica%22">Excerpta Medica </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7706726 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-114X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201492918%22">01492918 </searchLink><i>NLM ISO Abbreviation: </i>Clin Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41344973
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.clinthera.2025.10.011
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 73
    Titles:
      – TitleFull: Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pandya H
      – PersonEntity:
          Name:
            NameFull: Patel M
      – PersonEntity:
          Name:
            NameFull: Gillen M
      – PersonEntity:
          Name:
            NameFull: Reddy J
      – PersonEntity:
          Name:
            NameFull: Bednarczyk A
      – PersonEntity:
          Name:
            NameFull: Kokot M
      – PersonEntity:
          Name:
            NameFull: Tan Y
      – PersonEntity:
          Name:
            NameFull: Heijer M
      – PersonEntity:
          Name:
            NameFull: Andersson M
      – PersonEntity:
          Name:
            NameFull: Petullo D
      – PersonEntity:
          Name:
            NameFull: Jassal M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2026 Jan
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1879-114X
          Numbering:
            – Type: volume
              Value: 48
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Clinical therapeutics
              Type: main
ResultId 1